Abstract

Adeno-associated virus vectors (AAV) are reported to have a great potential for gene therapy, however, a major bottleneck for this kind of therapy is the limitation of production capacity. Higher specific AAV vector yield is often reported for adherent cell systems compared to cells in suspension, and a microcarrier-based culture is well established for the culture of anchored cells on a larger scale. The purpose of the present study was to explore how microcarrier cultures could provide a solution for the production of AAV vectors based on the triple plasmid transfection of HEK293T cells in a stirred tank bioreactor. In the present study, cells were grown and expanded in suspension, offering the ease of this type of operation, and were then anchored on microcarriers in order to proceed with transfection of the plasmids for transient AAV vector production. This process was developed in view of a bioreactor application in a 200 mL stirred-tank vessel where shear stress aspects were studied. Furthermore, amenability to a continuous process was studied. The present investigation provided a proof-of-concept of a continuous process based on microcarriers in a stirred-tank bioreactor.

Highlights

  • Accepted: 2 March 2022Gene therapy has the potential to be one of the great revolutions in medicine.It allows for treatment and potential cures for many debilitating diseases.Through the choice of vector, different tissues can be targeted making the treatment highly specific with few off-target effects

  • Production methods of associated virus (AAV) based on transient transfection require plasmids encoding the viral proteins and DNA, which are required for vector assembly

  • Medium D Cultivation was selected among five media for its potential to support transfection and AAV

Read more

Summary

Introduction

Accepted: 2 March 2022Gene therapy has the potential to be one of the great revolutions in medicine.It allows for treatment and potential cures for many debilitating diseases.Through the choice of vector, different tissues can be targeted making the treatment highly specific with few off-target effects. Gene therapy has the potential to be one of the great revolutions in medicine. It allows for treatment and potential cures for many debilitating diseases. Through the choice of vector, different tissues can be targeted making the treatment highly specific with few off-target effects. Most of the current AAV based therapies, are for rare diseases with low patient populations or have targets that require low doses. The current roadblock for the application of AAV based therapies for more prevalent diseases, or ones that require a high dose, is the limited manufacturing capacity [3]. An efficient scalable manufacturing platform for AAV vectors would allow for larger trials which would accelerate drug development and provide treatment options for diseases that affect larger populations

Objectives
Methods
Results
Conclusion
Full Text
Published version (Free)

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call